Mechanical properties and biochemical composition of rat cortical femur and tibia after long-term treatment with biosynthetic human growth hormone

Bone ◽  
1991 ◽  
Vol 12 (5) ◽  
pp. 353-359 ◽  
Author(s):  
P.H. Jørgensen ◽  
B. Bak ◽  
T.T. Andreassen
1979 ◽  
Vol 48 (3) ◽  
pp. 472-477 ◽  
Author(s):  
DANIEL RUDMAN ◽  
MICHAEL H. KUTNER ◽  
MARTIN A. GOLDSMITH ◽  
R.DWAIN BLACKSTON

Metabolism ◽  
1964 ◽  
Vol 13 (2) ◽  
pp. 152-160 ◽  
Author(s):  
Herbert Gershberg ◽  
Silvia Mari ◽  
Mildred Hulse ◽  
Henry St. Paul

1972 ◽  
Vol 69 (3) ◽  
pp. 417-433 ◽  
Author(s):  
Kerstin Hall ◽  
Patrick Olin

ABSTRACT Twenty patients with pituitary dwarfism were treated for nine months to 2½ years with human growth hormone (HGH) prepared according to Roos et al. (1963). Eleven of them had previously been given other HGH preparations for one to five years. During the first two years of treatment with HGH in a dose of 0.2 mg (0.4 IU) and 0.3 mg (0.6 IU) per kg body weight per week, the increase in growth rate was two- to threefold, and three- to fivefold, respectively. Long-termed treatment with HGH was accompanied by a decreasing ability of the hormone to stimulate growth. Cortisone acetate, in replacement doses, had no influence on this growth rate. During the present study only one of the 20 patients developed antibodies to HGH. The levels of sulphation factor (SF) activity in serum were low before treatment and increased significantly during treatment with HGH. There was a linear relationship between the SF activity in the serum and the slope of the growth carves. Both increased with the dose of HGH administered but decreased with duration of treatment.


1979 ◽  
Vol 92 (3) ◽  
pp. 385-397 ◽  
Author(s):  
Kazue Takano ◽  
Naomi Hizuka ◽  
Kazuo Shizume ◽  
Yoko Hasumi

ABSTRACT Eighteen patients with pituitary dwarfism were treated for 1 7/12 to 6 years with human growth hormone (hGH) at a dose of 0.19–0.62 unit (U) per kg of body weight per week. The mean increment in height was 2.0 ± 0.4 and 8.8 ± 0.5 cm/year before and the first year after treatment of hGH, respectively. A significant positive correlation was observed between serum levels of somatomedin A and growth rate, especially in children with bone age below 10 and a duration of treatment of less than one year (r = 0.66, P < 0.005). Long-term treatment with hGH was accompanied by a decreasing response. However, the serum levels of somatomedin A did not decrease significantly. Therefore, decreased growth increment in these situations was not due to decreased serum levels of somatomedin A.


1991 ◽  
Vol 130 (3) ◽  
pp. 435-441 ◽  
Author(s):  
M. E. Wilson ◽  
J. M. Tanner

ABSTRACT Female rhesus monkeys (n = 5), having normal pituitary function, were treated for 50 months with recombinant human growth hormone (rhGH; 250 μg/kg) 3 days/week (Monday, Wednesday and Friday) and rates of growth were compared with a group of age-matched untreated females (n = 6). Treatment was initiated at 20 months of age, approximately 10 months before the expected age of menarche. Long-term treatment with rhGH accelerated bone maturation and increased the velocity of increase in crown–rump length, tibia length and body weight. The period of acceleration occurred coincident with the occurrence of spontaneous puberty. Body measurements remained larger in the treated females until growth ceased. Long-term rhGH treatment increased final adult crown–rump length by some 3%, with a slight increase in tibia length and body weight, without having any untoward effects on reproductive capacity or health. One treated animal exhibited higher estimates of antibodies to rhGH throughout the study period, and this female also had a smaller increment in crown–rump length than the other treated females. These data suggest that long-term treatment of normal-pituitary females with rhGH augments crown–rump growth without any untoward effects of health. Journal of Endocrinology (1991) 130, 435–441


Sign in / Sign up

Export Citation Format

Share Document